This trial will compare the efficacy of lacosamide to an active comparator chosen based on standard of care in reducing seizure burden in neonates with uncontrolled seizures.
1 Primary · 12 Secondary · Reporting Duration: Across the first 48-hours of the Treatment Period (up to 48 hours)
Active Control
Experimental Treatment
32 Total Participants · 2 Treatment Groups
Primary Treatment: Lacosamide oral · No Placebo Group · Phase 2 & 3
Age < 18 · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: